Cerus Corporation Announces Contract with Canadian Blood Services for INTERCEPT Blood System for Platelets

Cerus Corporation (Nasdaq:CERS) today announced its contract with Canadian Blood Services for the INTERCEPT Blood System for Platelets. Canadian Blood Services is one of Canada’s two blood operators, serving all Canadian provinces and territories except Quebec.

“Today’s announcement is a significant milestone for Cerus as we enter the Canadian market. We are proud to partner with Canadian Blood Services to introduce pathogen inactivated platelets in Canada,” said Christian Boutemy, Cerus’ vice president, commercial operations EMEA, who is also responsible for Canada. “For nearly 30 years, Cerus has been dedicated to safeguarding the blood supply around the globe. We are pleased that Canadian Blood Services is taking this step to bring INTERCEPT to Canadians. We look forward to supporting them as they scale up production of pathogen inactivated platelets for patients throughout the region.”

“As an organization, we are committed to ensuring high quality blood components and to minimizing the risk of transfusion-transmitted infections. The INTERCEPT Blood System allows us to deliver on this goal,” said Dr. Graham D. Sher, Canadian Blood Services’ chief executive officer. “Our aim is to drive full adoption of pathogen reduced platelets once INTERCEPT is deployed across all of our production sites.”

Canadian Blood Services intends to implement pathogen reduced platelets in a gradual and measured manner, beginning in the Ottawa region in Fall 2021 subject to Health Canada approval. Broader implementation will begin after Cerus has attained Canadian regulatory approval for extension of pathogen reduced platelets’ shelf life from five days to seven.

Canadian Blood Services manufactures approximately 115,000 platelet doses annually.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy